Cargando…
NFB-17. "Optic Pathway findings in children with Neurofibromatosis type-1 (NF-1)
BACKGROUND/OBJECTIVES:Optic-pathway-glioma(OPG) represents the most common central-nervous tumor in children with neurofibromatosis type-1(NF1), occurring at an incidence of 15-20%. It is estimated that 1/3 of NF1 patients(pts) with OPG will need treatment. DESIGN-METHODS:We performed a retrospectiv...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165073/ http://dx.doi.org/10.1093/neuonc/noac079.478 |
_version_ | 1784720300572672000 |
---|---|
author | Roka, Kleoniki Kokkinou, Eleftheria Gavra, Maria Tsina, Efthymia Mparka, Konstantina Zarafonitis, Georgios Kosma, Konstantina Makrythanasis, Periklis Tzetis, Maria Chasiotou, Maria Kanaka-Gantenbein, Christina Pons, Roser Kattamis, Antonis |
author_facet | Roka, Kleoniki Kokkinou, Eleftheria Gavra, Maria Tsina, Efthymia Mparka, Konstantina Zarafonitis, Georgios Kosma, Konstantina Makrythanasis, Periklis Tzetis, Maria Chasiotou, Maria Kanaka-Gantenbein, Christina Pons, Roser Kattamis, Antonis |
author_sort | Roka, Kleoniki |
collection | PubMed |
description | BACKGROUND/OBJECTIVES:Optic-pathway-glioma(OPG) represents the most common central-nervous tumor in children with neurofibromatosis type-1(NF1), occurring at an incidence of 15-20%. It is estimated that 1/3 of NF1 patients(pts) with OPG will need treatment. DESIGN-METHODS:We performed a retrospective-review of all NF1-pts examined in the First Hellenic Multidisciplinary-Clinic – Center of Expertise for Neurocutaneous-disorders. Gender, age, MRI-radiological and ophthalmological findings, presence of OPG, management and outcome were analyzed. RESULTS:Since the establishment of the Clinic in 2016, 198pts with clinical diagnosis of NF1 based on NIH1988-criteria were evaluated and of them, 165(73 females, median age:5.5y, range:0.3-17.1y), who had imaging studies were included in this analysis. Eighty three pts(50.3%) had NF1-positive genetic-testing and 45NF1-family-history(27.3%). Imaging-findings from optic pathway were found in 55/165pts(28females). Percentage of pts with findings were 51.7% for <3y, 45.4% for 3-5y, 34.7% for 5-10y and 8.5% for >10y, respectively. The median age of their first brain-MRI imaging was 2.82y. Upon 1(st)MRI-imaging, 70.9% presented thickness of the optic nerves(ON)(25,4%bilateral, 20% optic chiasm,18.1% right ON, 10.0% left ON), 14.5%ON-tortuosity, 38.1%OPG(43,5% in the optic-chiasm) and 34.5% contrast enhancement. Of notice, 14pts presented an OPG after a median follow-up time of 1.79y. According to LGG2004-protocol indications for treatment, only 15/55pts had to be treated(27,2%, 5pts with family history, 33.3% between 5-10y). Severe vision-loss with need for immediate start of treatment upon 1(st)MRI imaging was found in 4pts, of whom 75% had family-history and first evaluation after the 5th year of age. Of notice, only 2pts<3y had to receive treatment, one with family-history and one with symptoms(diencephalic syndrome). CONCLUSIONS: Pts with NF1 should be followed by a multidisciplinary-team. Management should be individualized and imaging-studies can be limited to patients at high-risk. Positive family-history may be a negative prognostic factor for OP lesions. |
format | Online Article Text |
id | pubmed-9165073 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-91650732022-06-05 NFB-17. "Optic Pathway findings in children with Neurofibromatosis type-1 (NF-1) Roka, Kleoniki Kokkinou, Eleftheria Gavra, Maria Tsina, Efthymia Mparka, Konstantina Zarafonitis, Georgios Kosma, Konstantina Makrythanasis, Periklis Tzetis, Maria Chasiotou, Maria Kanaka-Gantenbein, Christina Pons, Roser Kattamis, Antonis Neuro Oncol Neurofibromatosis and other Predisposition Syndromes BACKGROUND/OBJECTIVES:Optic-pathway-glioma(OPG) represents the most common central-nervous tumor in children with neurofibromatosis type-1(NF1), occurring at an incidence of 15-20%. It is estimated that 1/3 of NF1 patients(pts) with OPG will need treatment. DESIGN-METHODS:We performed a retrospective-review of all NF1-pts examined in the First Hellenic Multidisciplinary-Clinic – Center of Expertise for Neurocutaneous-disorders. Gender, age, MRI-radiological and ophthalmological findings, presence of OPG, management and outcome were analyzed. RESULTS:Since the establishment of the Clinic in 2016, 198pts with clinical diagnosis of NF1 based on NIH1988-criteria were evaluated and of them, 165(73 females, median age:5.5y, range:0.3-17.1y), who had imaging studies were included in this analysis. Eighty three pts(50.3%) had NF1-positive genetic-testing and 45NF1-family-history(27.3%). Imaging-findings from optic pathway were found in 55/165pts(28females). Percentage of pts with findings were 51.7% for <3y, 45.4% for 3-5y, 34.7% for 5-10y and 8.5% for >10y, respectively. The median age of their first brain-MRI imaging was 2.82y. Upon 1(st)MRI-imaging, 70.9% presented thickness of the optic nerves(ON)(25,4%bilateral, 20% optic chiasm,18.1% right ON, 10.0% left ON), 14.5%ON-tortuosity, 38.1%OPG(43,5% in the optic-chiasm) and 34.5% contrast enhancement. Of notice, 14pts presented an OPG after a median follow-up time of 1.79y. According to LGG2004-protocol indications for treatment, only 15/55pts had to be treated(27,2%, 5pts with family history, 33.3% between 5-10y). Severe vision-loss with need for immediate start of treatment upon 1(st)MRI imaging was found in 4pts, of whom 75% had family-history and first evaluation after the 5th year of age. Of notice, only 2pts<3y had to receive treatment, one with family-history and one with symptoms(diencephalic syndrome). CONCLUSIONS: Pts with NF1 should be followed by a multidisciplinary-team. Management should be individualized and imaging-studies can be limited to patients at high-risk. Positive family-history may be a negative prognostic factor for OP lesions. Oxford University Press 2022-06-03 /pmc/articles/PMC9165073/ http://dx.doi.org/10.1093/neuonc/noac079.478 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Neurofibromatosis and other Predisposition Syndromes Roka, Kleoniki Kokkinou, Eleftheria Gavra, Maria Tsina, Efthymia Mparka, Konstantina Zarafonitis, Georgios Kosma, Konstantina Makrythanasis, Periklis Tzetis, Maria Chasiotou, Maria Kanaka-Gantenbein, Christina Pons, Roser Kattamis, Antonis NFB-17. "Optic Pathway findings in children with Neurofibromatosis type-1 (NF-1) |
title | NFB-17. "Optic Pathway findings in children with Neurofibromatosis type-1 (NF-1) |
title_full | NFB-17. "Optic Pathway findings in children with Neurofibromatosis type-1 (NF-1) |
title_fullStr | NFB-17. "Optic Pathway findings in children with Neurofibromatosis type-1 (NF-1) |
title_full_unstemmed | NFB-17. "Optic Pathway findings in children with Neurofibromatosis type-1 (NF-1) |
title_short | NFB-17. "Optic Pathway findings in children with Neurofibromatosis type-1 (NF-1) |
title_sort | nfb-17. "optic pathway findings in children with neurofibromatosis type-1 (nf-1) |
topic | Neurofibromatosis and other Predisposition Syndromes |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165073/ http://dx.doi.org/10.1093/neuonc/noac079.478 |
work_keys_str_mv | AT rokakleoniki nfb17opticpathwayfindingsinchildrenwithneurofibromatosistype1nf1 AT kokkinoueleftheria nfb17opticpathwayfindingsinchildrenwithneurofibromatosistype1nf1 AT gavramaria nfb17opticpathwayfindingsinchildrenwithneurofibromatosistype1nf1 AT tsinaefthymia nfb17opticpathwayfindingsinchildrenwithneurofibromatosistype1nf1 AT mparkakonstantina nfb17opticpathwayfindingsinchildrenwithneurofibromatosistype1nf1 AT zarafonitisgeorgios nfb17opticpathwayfindingsinchildrenwithneurofibromatosistype1nf1 AT kosmakonstantina nfb17opticpathwayfindingsinchildrenwithneurofibromatosistype1nf1 AT makrythanasisperiklis nfb17opticpathwayfindingsinchildrenwithneurofibromatosistype1nf1 AT tzetismaria nfb17opticpathwayfindingsinchildrenwithneurofibromatosistype1nf1 AT chasiotoumaria nfb17opticpathwayfindingsinchildrenwithneurofibromatosistype1nf1 AT kanakagantenbeinchristina nfb17opticpathwayfindingsinchildrenwithneurofibromatosistype1nf1 AT ponsroser nfb17opticpathwayfindingsinchildrenwithneurofibromatosistype1nf1 AT kattamisantonis nfb17opticpathwayfindingsinchildrenwithneurofibromatosistype1nf1 |